ATP5F1A and glioblastoma: Consequently, msiCAT-tailed ATP5α enhances GBM cell resistance to programmed cell death induced by staurosporine (STS) and temozolomide (TMZ), thereby fostering cancer cell survival, proliferation, and migration.